The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, said that AbbVie (ABBV) has expanded its collaboration to further explore Calibr-Skaggs' switchable CAR-T or sCAR-T platform in solid tumor indications and autoimmune diseases.
As per the terms of the license deal, AbbVie will pay Calibr-Skaggs an upfront license fee and maintain exclusive access to Calibr-Skaggs' switchable CAR-T platform for a term of up to five years.
AbbVie also has the option to license existing Calibr-Skaggs cell therapy programs under development for hematological and solid tumors, including Calibr-Skaggs' lead program and will have the option to explore the applicability of sCAR-Ts in autoimmune diseases. Calibr-Skaggs is eligible to receive success-based milestone payments and royalties.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.